Avita Medical reports 2Q EPS (38c), consensus (36c)

Reports Q2 revenue $18.42M vs. $15.2M last year. Jim Corbett, Chief Executive Officer of Avita Medical (RCEL), commented: “Although the first half of 2025 tested our resilience and slowed our pace, a resolution is now underway and our strategic direction hasn’t changed. The data tells the story: RECELL reduces hospital stays by 36%, Cohealyx achieves graft readiness in as little as five days. We’re also grateful for CMS’s support in expanding access to RECELL for Medicare beneficiaries with inpatient trauma wounds with the NTAP. We’re accelerating time to heal, time to recover, and time to deliver value, to patients and providers alike.”